Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of four proton pump inhibitors in gastroesophageal reflux disease
IRCT20171007036616N1Phase 4Completed
- Sponsor
- Dr. Abidi Pharmaceuticals
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of omeprazole, pantoprazole, esomeprazole and lansoprazole in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Dr. Abidi Pharmaceuticals. Primary endpoints: Chronic reflux symptoms after 8 weeks and Treatment satisfaction after 8 weeks. Started Jan 2018; status: completed.
02
Drugs
omeprazolepantoprazoleesomeprazolelansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on IRCT20171007036616N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171007036616N1.